Latest Pharma Insights
Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - December 31, 2025
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - December 31, 2025
The Top Five Pharma Stories Of 2025
There has not been a dull moment in the biopharma sector this year. With just a day left, and in no particular order, Scrip takes a look at five of the biggest stories of 2025.
Scrip - December 31, 2025
There has not been a dull moment in the biopharma sector this year. With just a day left, and in no particular order, Scrip takes a look at five of the biggest stories of 2025.
Scrip - December 31, 2025
Reckitt Spies Malaysia Growth Potential
Reckitt is partnering with DKSH to take its consumer health business in Malaysia to the next level.
HBW Insight - December 31, 2025
Reckitt is partnering with DKSH to take its consumer health business in Malaysia to the next level.
HBW Insight - December 31, 2025
Medtronic Faces Class I Recall As FDA Flags Heart Vent Catheter Performance Risk
In a letter to its customers, Medtronic said it had also received 41 complaints indicating that the catheters were not retaining their intended shape when bent. The FDA issued an early alert about the recall in August but did not at that time assign a recall class.
Medtech Insight - December 31, 2025
In a letter to its customers, Medtronic said it had also received 41 complaints indicating that the catheters were not retaining their intended shape when bent. The FDA issued an early alert about the recall in August but did not at that time assign a recall class.
Medtech Insight - December 31, 2025
Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - December 31, 2025
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - December 31, 2025
The Top Five Pharma Stories Of 2025
There has not been a dull moment in the biopharma sector this year. With just a day left, and in no particular order, Scrip takes a look at five of the biggest stories of 2025.
Scrip - December 31, 2025
There has not been a dull moment in the biopharma sector this year. With just a day left, and in no particular order, Scrip takes a look at five of the biggest stories of 2025.
Scrip - December 31, 2025
Medtronic Faces Class I Recall As FDA Flags Heart Vent Catheter Performance Risk
In a letter to its customers, Medtronic said it had also received 41 complaints indicating that the catheters were not retaining their intended shape when bent. The FDA issued an early alert about the recall in August but did not at that time assign a recall class.
Medtech Insight - December 31, 2025
In a letter to its customers, Medtronic said it had also received 41 complaints indicating that the catheters were not retaining their intended shape when bent. The FDA issued an early alert about the recall in August but did not at that time assign a recall class.
Medtech Insight - December 31, 2025
Reckitt Spies Malaysia Growth Potential
Reckitt is partnering with DKSH to take its consumer health business in Malaysia to the next level.
HBW Insight - December 31, 2025
Reckitt is partnering with DKSH to take its consumer health business in Malaysia to the next level.
HBW Insight - December 31, 2025
Alvotech Sees Out 2025 With Simponi Biosimilar Debut In Europe
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.
Generics Bulletin - December 22, 2025
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.
Generics Bulletin - December 22, 2025
BsUFA IV: Approval Criteria Shift May Mean US FDA User Fee Changes
A Teva official suggested the increasing reliance on analytical characterizations rather than clinical studies to show biosimilarity should warrant user fee structure changes.
Generics Bulletin - December 22, 2025
A Teva official suggested the increasing reliance on analytical characterizations rather than clinical studies to show biosimilarity should warrant user fee structure changes.
Generics Bulletin - December 22, 2025
Biocon Strikes Aflibercept Deal And Launches Liraglutide In Europe
Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.
Generics Bulletin - December 22, 2025
Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.
Generics Bulletin - December 22, 2025
Europe Leads Charge As Private Equity Roars Back Into Off-Patent Pharma
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
Generics Bulletin - December 22, 2025
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
Generics Bulletin - December 22, 2025
Podcast: “We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Topadur Sees Future Expansion From Wound Healing Into Longevity
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
How MFN And IRP Convergence Are Rewriting Biotech’s Playbook
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025